secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMGC Holdings Inc. (ELAB)
CIK:        0001840563
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001213900-25-124162
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMGC subsidiaries advance drug discovery program and achieve AS9100 certification
--------------------------------------------------------------------------------

- NorthStrive Biosciences advances to Phase III of AI drug discovery program with YuvaBio, targeting muscle preservation via mitochondrial function.
- Phase III will generate biological data on AI-selected compounds, including cytotoxicity screening and ANT1 expression testing over 6-9 weeks.
- AGA Precision Systems achieves AS9100 certification, the globally recognized quality standard for aerospace, defense, and space industries.
- AGA is evaluating humanoid robotics integration for advanced manufacturing; no assurance of implementation or benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840563/000121390025124162/0001213900-25-124162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840563/000121390025124162/ea0270503-8k_pmgchold.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-124162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer